This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Novartis AG

Drug Names(s): deferasirox, ICL670, Exjade FCT, Jadenu

Description: ICL670 is an oral iron chelator that has been shown to induce iron excretion preclinically and clinically. ICL670 binds with high affinity to iron ions to facilitate their removal from the body.

Iron overload is associated with severe morbidity, particularly in patients who suffer from transfusion-dependent anemias, such as thalassemia, sickle cell disease, and myelodysplastic syndromes. Because no physiologic means exists for the excretion of excess iron, the human body is unable to actively regulate iron concentrations. Iron chelators form a complex with the excess iron in the tissues, and facilitate excretion from the body. Chelation therapies reduce tissue iron stores, prevent iron-induced organ damage, and reduce morbidity and mortality.

Exjade News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug